Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients

Pazopanib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Retrospective analyses have shown that an increased median progression-free survival and tumor shrinkage appear in patients with higher plasma trough levels (C ). Therefore, patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-12, Vol.22 (23), p.5738-5746
Hauptverfasser:	Verheijen, Remy B, Bins, Sander, Mathijssen, Ron H J, Lolkema, Martijn P, van Doorn, Leni, Schellens, Jan H M, Beijnen, Jos H, Langenberg, Marlies H G, Huitema, Alwin D R, Steeghs, Neeltje
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Carcinoma, Renal Cell - drug therapy Disease-Free Survival Feasibility Studies Female Humans Kidney Neoplasms - drug therapy Male Middle Aged Prospective Studies Protein Kinase Inhibitors - administration & dosage Pyrimidines - administration & dosage Sarcoma - drug therapy Sulfonamides - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pazopanib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Retrospective analyses have shown that an increased median progression-free survival and tumor shrinkage appear in patients with higher plasma trough levels (C ). Therefore, patients with low C might benefit from pharmacokinetically guided individualized dosing. We conducted a prospective multicenter trial in 30 patients with advanced solid tumors. Pazopanib C was measured weekly by LC-MS/MS. At weeks 3, 5, and 7, the pazopanib dose was increased if the measured C was
ISSN:	1078-0432 1557-3265
DOI:	10.1158/1078-0432.ccr-16-1255